FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308383984> ?p ?o ?g. }

• W4308383984 abstract "<h3>Background</h3> CD8 immune phenotype status is associated with response to anti–PD-L1 therapy in aUC. To assess the tumor microenvironment in aUC, we developed machine learning (ML)–based models to identify cell types and tissue regions in digitized H&E-stained WSI from the JAVELIN Bladder 100 trial, which showed that avelumab (anti–PD-L1) first-line maintenance plus best supportive care (BSC) significantly prolonged overall survival vs BSC alone in patients with aUC. ML-quantified features were used for subsequent slide-level immune phenotyping of these clinical trial samples. <h3>Methods</h3> Models previously trained using samples from The Cancer Genome Atlas were refined using 25,926 tissue regions annotations and 183,259 cell type annotations on 704 formalin-fixed, paraffin-embedded, H&E-stained WSI scanned on MIRAX (40x) to identify artifacts, tissue regions (cancer, stroma, and necrosis), and cell types (cancer epithelial cells, lymphocytes, macrophages, fibroblasts, and granulocytes). Precision, recall, and F1 scores were calculated to evaluate model performance. Following pathologist guidelines, H&E slide-level digital immune phenotypes (excluded, inflamed, and desert) were determined using thresholds of lymphocyte area within stroma and proportion of lymphocytes vs all cells in cancer epithelium. The distribution of H&E slide-level digital immune phenotypes was calculated across samples in both trial arms, and the association between immune phenotype and CD8 score at the tumor core was determined using the Kruskal-Wallis and Mann-Whitney U tests. <h3>Results</h3> Precision, recall, and F1 scores for model predictions were comparable to those of an average annotator across cell types. The model’s concordance with consensus was also higher than that of an average human annotator (Cohen’s kappa, 0.816 vs 0. 680). Calculation of the distribution of H&E slide-level digital immune phenotypes across trial arms showed that most samples in each arm had an excluded immune phenotype, and a slightly higher proportion of samples in the BSC-only arm had an inflamed phenotype. Association between immune phenotype and the gold-standard CD8 immunohistochemistry (IHC) score at the tumor core showed that samples with the inflamed immune phenotype had higher CD8 scores at the tumor core than samples with the excluded immune phenotype (Mann-Whitney, p<0.026). <h3>Conclusions</h3> We show an AI-powered approach to determine slide-level immune phenotypes directly from digitized H&E-stained WSI of clinical aUC samples. An association between inflamed immune phenotypes and higher CD8 scores at the tumor core supports the potential use of this method as an alternative to CD8 IHC-based approaches to identify patients who may derive optimal benefit from anti–PD-L1 treatment. <h3>Acknowledgements</h3> This research was supported by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945) as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer. <h3>Trial Registration</h3> NCT02603432 (ClinicalTrials.gov) <h3>Ethics Approval</h3> The trial protocol was approved by the independent ethics committee or institutional review board at each participating center." @default.
• W4308383984 created "2022-11-11" @default.
• W4308383984 creator A5020009010 @default.
• W4308383984 creator A5020484271 @default.
• W4308383984 creator A5041131861 @default.
• W4308383984 creator A5041526428 @default.
• W4308383984 creator A5043261380 @default.
• W4308383984 creator A5046578183 @default.
• W4308383984 creator A5055511889 @default.
• W4308383984 creator A5060057792 @default.
• W4308383984 creator A5060908808 @default.
• W4308383984 creator A5061896696 @default.
• W4308383984 creator A5073820933 @default.
• W4308383984 creator A5091489475 @default.
• W4308383984 date "2022-11-01" @default.
• W4308383984 modified "2023-09-25" @default.
• W4308383984 title "554 Artificial intelligence (AI)-powered immune phenotyping of advanced or metastatic urothelial carcinoma (aUC) clinical trial samples from hematoxylin and eosin (H&E)-stained whole slide images (WSI)" @default.
• W4308383984 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0554" @default.
• W4308383984 hasPublicationYear "2022" @default.
• W4308383984 type Work @default.
• W4308383984 citedByCount "0" @default.
• W4308383984 crossrefType "proceedings-article" @default.
• W4308383984 hasAuthorship W4308383984A5020009010 @default.
• W4308383984 hasAuthorship W4308383984A5020484271 @default.
• W4308383984 hasAuthorship W4308383984A5041131861 @default.
• W4308383984 hasAuthorship W4308383984A5041526428 @default.
• W4308383984 hasAuthorship W4308383984A5043261380 @default.
• W4308383984 hasAuthorship W4308383984A5046578183 @default.
• W4308383984 hasAuthorship W4308383984A5055511889 @default.
• W4308383984 hasAuthorship W4308383984A5060057792 @default.
• W4308383984 hasAuthorship W4308383984A5060908808 @default.
• W4308383984 hasAuthorship W4308383984A5061896696 @default.
• W4308383984 hasAuthorship W4308383984A5073820933 @default.
• W4308383984 hasAuthorship W4308383984A5091489475 @default.
• W4308383984 hasBestOaLocation W43083839841 @default.
• W4308383984 hasConcept C125473707 @default.
• W4308383984 hasConcept C142724271 @default.
• W4308383984 hasConcept C167672396 @default.
• W4308383984 hasConcept C203014093 @default.
• W4308383984 hasConcept C204232928 @default.
• W4308383984 hasConcept C2776107976 @default.
• W4308383984 hasConcept C2777522853 @default.
• W4308383984 hasConcept C2777701055 @default.
• W4308383984 hasConcept C2778326572 @default.
• W4308383984 hasConcept C2780057760 @default.
• W4308383984 hasConcept C502942594 @default.
• W4308383984 hasConcept C52124034 @default.
• W4308383984 hasConcept C71924100 @default.
• W4308383984 hasConcept C86803240 @default.
• W4308383984 hasConcept C8891405 @default.
• W4308383984 hasConceptScore W4308383984C125473707 @default.
• W4308383984 hasConceptScore W4308383984C142724271 @default.
• W4308383984 hasConceptScore W4308383984C167672396 @default.
• W4308383984 hasConceptScore W4308383984C203014093 @default.
• W4308383984 hasConceptScore W4308383984C204232928 @default.
• W4308383984 hasConceptScore W4308383984C2776107976 @default.
• W4308383984 hasConceptScore W4308383984C2777522853 @default.
• W4308383984 hasConceptScore W4308383984C2777701055 @default.
• W4308383984 hasConceptScore W4308383984C2778326572 @default.
• W4308383984 hasConceptScore W4308383984C2780057760 @default.
• W4308383984 hasConceptScore W4308383984C502942594 @default.
• W4308383984 hasConceptScore W4308383984C52124034 @default.
• W4308383984 hasConceptScore W4308383984C71924100 @default.
• W4308383984 hasConceptScore W4308383984C86803240 @default.
• W4308383984 hasConceptScore W4308383984C8891405 @default.
• W4308383984 hasLocation W43083839841 @default.
• W4308383984 hasOpenAccess W4308383984 @default.
• W4308383984 hasPrimaryLocation W43083839841 @default.
• W4308383984 hasRelatedWork W2898379310 @default.
• W4308383984 hasRelatedWork W2904909612 @default.
• W4308383984 hasRelatedWork W2908970744 @default.
• W4308383984 hasRelatedWork W3003920454 @default.
• W4308383984 hasRelatedWork W3025076282 @default.
• W4308383984 hasRelatedWork W3034916528 @default.
• W4308383984 hasRelatedWork W3099981825 @default.
• W4308383984 hasRelatedWork W4291378227 @default.
• W4308383984 hasRelatedWork W4362541088 @default.
• W4308383984 hasRelatedWork W4362733751 @default.
• W4308383984 isParatext "false" @default.
• W4308383984 isRetracted "false" @default.
• W4308383984 workType "article" @default.